All In Biotech

Drug Trial Radar · NCT07843290

A Study of JYP0066 Cream in Mild-to-Moderate Atopic Dermatitis

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of JYP0066 Topical Cream in Adolescents and Adults With Mild-to-Moderate Atopic Dermatitis

Last checked: Nov 20, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 160 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

160

Planned (sponsor's estimate)

Start

Sep 30, 2026

Primary completion

Aug 30, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Guangzhou JOYO Pharma Co., LtdIndustry
Sponsor type
Industry
First posted
Sep 28, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 12 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2 research study testing an investigational topical cream called JYP0066 for the treatment of mild-to-moderate atopic dermatitis (eczema) in teenagers (12-17 years old) and adults. The study will check whether JYP0066 cream can reduce eczema signs and symptoms such as redness, itching, dryness, and skin thickening, and whether it is safe and well tolerated. Participants will be randomly assigned to one of four groups: they will apply either 4%, 3%, or 2% JYP0066 cream, or a matching placebo cream, to eczema-affected skin twice a day for 8 weeks. All creams will look the same. This helps the study compare which concentration works best and how safe each one is.

Conditions

  • Atopic Dermatitis (AD)

Interventions

  • JYP0066 4% topical creamDrug

    applied twice daily (BID) to affected skin areas for 8 weeks

  • 3% JYP0066 topical creamDrug

    applied twice daily (BID) for 8 weeks

  • 2% JYP0066 topical creamDrug

    applied twice daily (BID) for 8 weeks

  • Matching placebo cream (vehicle, no active ingredient)Drug

    applied twice daily (BID) for 8 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent change from baseline in EASI score at Week 8Time frame: Baseline to Week 8

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.